Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (101-110 of 825) with videos related to

Pageof 83
Sort By:
Oncology (Williston Park, N.Y.)|July 1, 1987
Current status of chemotherapy for urothelial tract tumorsC N Sternberg, H I Scher
Hematology/Oncology Clinics of North America|February 1, 1992
Chemotherapy for metastatic bladder cancerP W Kantoff, H I Scher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancerH I Scher, W K Kelly
Seminars in Oncology|September 11, 1999
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer CenterS F Slovin, H I Scher
Nature Reviews. Neurology|March 10, 2010
Migraine: migraine with aura increases the risk of strokeAnn I Scher, Lenore J Launer
Cephalalgia : an International Journal of Headache|August 10, 2013
Epidemiology and classification of post-traumatic headache: what do we know and how do we move forward? Comment on Lucas et al., "Prevalence and characterization of headache following mild TBI"Ann I Scher, Teshamae S Monteith
Cancer|August 5, 1998
Detectable tumor cells in the blood and bone marrow: smoke or fire?S F Slovin, H I Scher
Urologic Oncology|March 31, 2015
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapyGabriel P Haas, Howard I Scher
Surgical Oncology Clinics of North America|October 6, 1997
Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experienceW R Fair, H I Scher
The Cancer Journal From Scientific American|July 1, 1997
'Casodex': defining the role of antiandrogensJ A McCaffrey, H I Scher
Pageof 83

Showing results (101-110 of 825) with videos related to

Sort By:
Pageof 83
Oncology (Williston Park, N.Y.)|July 1, 1987
Current status of chemotherapy for urothelial tract tumorsC N Sternberg, H I Scher
Hematology/Oncology Clinics of North America|February 1, 1992
Chemotherapy for metastatic bladder cancerP W Kantoff, H I Scher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancerH I Scher, W K Kelly
Seminars in Oncology|September 11, 1999
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer CenterS F Slovin, H I Scher
Nature Reviews. Neurology|March 10, 2010
Migraine: migraine with aura increases the risk of strokeAnn I Scher, Lenore J Launer
Cephalalgia : an International Journal of Headache|August 10, 2013
Epidemiology and classification of post-traumatic headache: what do we know and how do we move forward? Comment on Lucas et al., "Prevalence and characterization of headache following mild TBI"Ann I Scher, Teshamae S Monteith
Cancer|August 5, 1998
Detectable tumor cells in the blood and bone marrow: smoke or fire?S F Slovin, H I Scher
Urologic Oncology|March 31, 2015
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapyGabriel P Haas, Howard I Scher
Surgical Oncology Clinics of North America|October 6, 1997
Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experienceW R Fair, H I Scher
The Cancer Journal From Scientific American|July 1, 1997
'Casodex': defining the role of antiandrogensJ A McCaffrey, H I Scher
Pageof 83